Latest Breaking News On - Sylvie berrebi frazer hall - Page 3 : comparemela.com

Oxurion NV: Oxurion Announces New Data on THR-149 Phase 2 Clinical Trial (KALAHARI) in DME at the Angiogenesis, Exudation, and Degeneration 2022 Conference

Post-hoc analysis reveals >9 letter gain in mean BCVA that was maintained for the remaining four months of the trial after the last THR-149 injection with no rescue treatment requiredThese gains were seen

United statesRegion flamandeTom graneyMichael dillenArshadm khananiSylvie berrebi frazer hallChristopher brinzeyCompany annualClinical research at sierra eye associatesEuronext brusselsOptical coherence tomographyCentral subfield thicknessClinical researchSierra eye associatesChief executive officer

Oxurion to Participate in the 2022 BIO CEO and Investor Conference

Oxurion to Participate in the 2022 BIO CEO and Investor Conference
morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.

United statesRegion flamandeTom graneyMichael dillenSylvie berrebi frazer hallChristopher brinzeyMarriott marquisEuronext brusselsInvestor conference

Oxurion NV: OXURION to Participate in the 10th edition of Degroof Petercam s Healthcare Conference

Leuven, BELGIUM, Boston, MA, US - January 18, 2022 - 08.00 AM CET - Oxurion NV(Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic

United statesRegion flamandeTom graneyMichael dillenSylvie berrebi frazer hallChristopher brinzeyCompany annualEuronext brusselsDegroof petercamHealthcare conference

Oxurion NV: Oxurion Provides Update on Clinical Pipeline Progress

Completed Patient Enrollment for Part A of Phase 2 INTEGRAL Trial Evaluating THR-687 for treatment of Diabetic Macular Edema (DME) in treatment naïve subjects US IRB Approval of Protocol Amendment

United statesRegion flamandeTom graneyMichael dillenArshadm khananiSylvie berrebi frazer hallChristopher brinzeyCompany annualClinical research at sierra eye associatesCompleted patient enrollmentDiabetic macular edemaProtocol amendmentEuronext brusselsPatient enrollmentAge related macular degenerationRetinal vein occlusion

Oxurion NV: OXURION to Present at the H C Wainwright BioConnect 2022 Virtual Conference

Leuven, BELGIUM, Boston, MA, US - January 4, 2022 - 06.00 PM CET - Oxurion NV(Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic

United statesRegion flamandeTom graneyMichael dillenHc wainwright bioconnectSylvie berrebi frazer hallChristopher brinzeyCompany annualCorporate developmentEuronext brussels